Global Postmenopausal Hormone Therapy Market

Postmenopausal Hormone Therapy Market
- Global Industry Analysis, Size, Share,
Growth, Trends and Forecast 2016 - 2024
Transparency Market Research Reports incorporated a definite
business overview and investigation inclines on
"Postmenopausal Hormone Therapy Market". This report
likewise incorporates more illumination about fundamental
review of the business including definitions, requisitions and
worldwide business sector industry structure.
Tropical spastic paraparesis (TSP) also called as HTLV-1–
associated myelopathy (HAM) is a type of tropical
myeloneuropathies caused by the human T-lymphotrophic virus
1 (HTLV-1). Although initially described in tropical countries,
TSP has also been found in temperate regions such as southern
Japan. HTLV-1 virus belongs to the Retroviridae family, and
preferentially infects CD4 lymphoid cells.
The virus has been known to cause certain kinds of leukemia
and lymphoma and is transmitted through exposure to infected
blood, sexual contact, and use of illegal intravenous drugs. As
the virus is also known to spread through breast milk, mothers
infected with HTLV-1 virus must avoid breast feeding.

According to an article published in the journal Frontiers in
Microbiology in 2012, the HTLV-1 virus is prevalent in certain
regions including the Southwestern part of Japan, sub-Saharan
Africa and South America, the Caribbean area, and certain areas
of Middle East and Australo-Melanesia.
Browse Full Research Report on Postmenopausal Hormone
Therapy Market:
http://www.transparencymarketresearch.com/postmenopausal-hormonetherapy-market.html
The study also estimates that 5 million to 10 million individuals
have been affected globally with HTLV1 virus, however various
other publications estimate the global prevalence of 10 million
to 20 million.
HTLV-1-associated myelopathy mostly affects the spinal cord,
and results in an upper motor neurone syndrome, that usually
affects lower limbs. Spastic paraparesis or paraplegia is the main
characteristic of the infection. Tropical spastic paraparesis
results in demyelination, inflammation and necrotic lesions in
spinal cord. The progressive disease is associated with
degeneration of neurons in the spinal cord, and results in gradual
paralysis of the lower limbs.
Other rare symptoms include optic atrophy, reduced ankle reflex
and cranial nerve lesions. An article published in journal Revue

Neurologique in 2012, more than 90% of the tropical spastic
paraparesis cases, the neurological features involved urinary
bladder disturbance, spasticity and/or hyperreflexia of the lower
extremities, and lower extremity muscle weakness.
Various immunoassay kits are available for diagnosis of HTLV-1
virus. Companies manufacturing such diagnostic kits include
MP Biomedicals LLC, Fujirebio, Inc., Quest Diagnostics,
DiaSorin S.p.A. Although the disease cannot be cured
completely, medications are available for management of
symptoms. Corticosteroids such as methylprednisolone are
prescribed to decrease the inflammation of the spinal cord, while
pain is treated with non-steroidal anti-inflammatory
medications.
Symptoms of urinary dysfunction can be treated by prescribing
darifenacin, oxybutynin, tamsulosin, terazosin, and other drugs
which reduce the activity of bladder muscles. National Institute
of Neurological Disorders and Stroke (NINDS) is currently
conducting phase I clinical trials for Hu MiK-Beta-1.
The investigational drug is monoclonal antibody directed toward
IL-2/IL-15R-Beta Subunit which blocks IL-15 action.
Washington University School of Medicine in association with
Merck Sharp & Dohme Corp. is also conducting phase II trials
for Raltegravir.

Various other institutes are also conducting research programs
for discovering new and effective treatment options for Tropical
spastic paraparesis. Scientists have also tried antiretroviral
agents for treatment of HTLV-1 infections. Gradual progress in
the research activities is expected to launch more treatment
drugs and expand the market in the future.
Due to low and restricted geographical prevalence of the
disease, the market for tropical spastic paraparesis is small.
Government initiative for increasing awareness of the disease
and its available treatment may curb the spread of infections.
Lack of sufficient information on geographical prevalence, and
epidemiology has restricted the research activities. These factors
will also be responsible for a slower global market growth.
About Us
Transparency Market Research (TMR) is a global market
intelligence company providing business information reports
and services. The company’s exclusive blend of quantitative
forecasting and trend analysis provides forward-looking insight
for thousands of decision makers. TMR’s experienced team of
analysts, researchers, and consultants use proprietary data

sources and various tools and techniques to gather and analyze
information.
TMR’s data repository is continuously updated and revised by a
team of research experts so that it always reflects the latest
trends and information. With extensive research and analysis
capabilities, Transparency Market Research employs rigorous
primary and secondary research techniques to develop
distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com